XOMA Corp
NASDAQ:XOMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
XOMA Corp
NASDAQ:XOMA
|
US |
|
BLIS Technologies Ltd
NZX:BLT
|
NZ |
|
Adese Gayrimenkul Yatirim AS
IST:ADESE.E
|
TR |
|
UTI Asset Management Company Ltd
NSE:UTIAMC
|
IN |
|
S
|
Solteq Oyj
OMXH:SOLTEQ
|
FI |
|
Beyond Air Inc
NASDAQ:XAIR
|
US |
|
Graphic Packaging Holding Co
NYSE:GPK
|
US |
|
Yuanli Chemical Group Co Ltd
SSE:603217
|
CN |
|
B
|
Bay Capital PLC
LSE:BAY
|
JE |
|
S
|
Spinnaker Acquisitions PLC
LSE:SPAQ
|
UK |
XOMA Corp
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
Performance: XOMA reported full year total GAAP income and revenue of $52.1 million and GAAP net income of $31.7 million for 2025, a swing from a $13.8 million GAAP net loss in 2024.
Revenue mix: Total cash receipts were $50.5 million, including $34 million of royalty receipts (up 68% year-over-year), and portfolio receipts surpassed $50 million in 2025.
Portfolio build: The company added 22 assets in 2025, growing the portfolio from ~60 assets in 2023 to over 120 today, with 7 commercial programs and 14 registrational-stage programs.
Capital allocation: XOMA deployed ~$25 million to acquire royalty and milestone rights, returned $16 million via buybacks (retiring ~648,000 shares, ~5% of shares outstanding) and ended the year with ~ $83 million of unrestricted cash.
Clinical risk: Two Phase III setbacks (Rezolute in congenital hyperinsulinism and Gossamer seralutinib in PAH) occurred but both companies plan FDA discussions and further analysis; several late-stage catalysts are expected in 2026.
Strategic deals: Executed a December revenue-share transaction with Takeda (9 programs) and transactions with BioInvent, Generation Bio and others to add potential royalties/milestones (Takeda-related milestone potential up to $853 million across 9 assets noted).
Litigation: XOMA initiated litigation against Janssen (Tremfya) asserting breach of contract and unjust enrichment; management and advisers express confidence but note litigation uncertainty.
Outlook: Management expects royalties from currently approved products alone could cover breakeven operating cash flows by 2027 if current trends continue.
